Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 164
Filter
1.
Proc Natl Acad Sci U S A ; 114(17): E3526-E3535, 2017 04 25.
Article in English | MEDLINE | ID: mdl-28396432

ABSTRACT

Narcolepsy is a sleep disorder caused by the loss of orexin (hypocretin)-producing neurons and marked by excessive daytime sleepiness and a sudden weakening of muscle tone, or cataplexy, often triggered by strong emotions. In a mouse model for narcolepsy, we previously demonstrated that serotonin neurons of the dorsal raphe nucleus (DRN) mediate the suppression of cataplexy-like episodes (CLEs) by orexin neurons. Using an optogenetic tool, in this paper we show that the acute activation of DRN serotonin neuron terminals in the amygdala, but not in nuclei involved in regulating rapid eye-movement sleep and atonia, suppressed CLEs. Not only did stimulating serotonin nerve terminals reduce amygdala activity, but the chemogenetic inhibition of the amygdala using designer receptors exclusively activated by designer drugs also drastically decreased CLEs, whereas chemogenetic activation increased them. Moreover, the optogenetic inhibition of serotonin nerve terminals in the amygdala blocked the anticataplectic effects of orexin signaling in DRN serotonin neurons. Taken together, the results suggest that DRN serotonin neurons, as a downstream target of orexin neurons, inhibit cataplexy by reducing the activity of amygdala as a center for emotional processing.


Subject(s)
Amygdala , Catalepsy , Dorsal Raphe Nucleus , Serotonergic Neurons/metabolism , Signal Transduction , Amygdala/metabolism , Amygdala/pathology , Amygdala/physiopathology , Animals , Catalepsy/genetics , Catalepsy/metabolism , Catalepsy/pathology , Catalepsy/physiopathology , Dorsal Raphe Nucleus/metabolism , Dorsal Raphe Nucleus/pathology , Dorsal Raphe Nucleus/physiopathology , Eye Movements , Male , Mice , Mice, Knockout , Serotonergic Neurons/pathology , Serotonin/metabolism
2.
Drug Chem Toxicol ; 42(2): 122-129, 2019 Mar.
Article in English | MEDLINE | ID: mdl-29250976

ABSTRACT

Medicinal plants, as new drugs, are considered for treatment of insomnia, anxiety, depression, confusion, nausea, and vomiting symptoms. The current study aimed to evaluate the neuroprotective and antiemetic effects of Albizia. julibrissin Durazz. flower extract in the chickens. Emesis was induced by copper sulfate and ipecac (60 and 600 mg/kg, orally, respectively) and the methanolic extract (50, 100, and 200 mg/kg) were injected intraperitoneally (i.p.). Mitochondrial function, lipid peroxidation (LPO), protein carbonyl (PC) content, and catalase activity as biomarkers of oxidative damage were evaluated in the brain mitochondria. All doses of extract showed significant (p < 0.001) antiemetic activity against induced emesis by copper sulfate and ipecac. Brain mitochondria function (by 50, 100, and 200 mg/kg of extract) were increased 48%, 85%, and 90% against emesis induced by ipecac and 32%, 18%, and 24% against emesis induced by copper sulfate, respectively. LPO and PC contents were significantly decreased after the administration of extract in emesis induced by copper sulfate and ipecac. A significant decrease (p < 0.01) of CAT activity was observed in the extract (200 mg/kg) group in emesis induced by copper sulfate in chickens brain mitochondria. The present study suggests that the extract had antiemetic effects against emesis induced by copper sulfate and ipecac in young chickens via peripheral and central mechanisms. Neuroprotective effect of the extract could be due to the increase in bioactive compounds, plasma antioxidants, or direct free radical scavenging that could prevent lipid and protein alteration and impede the formation of oxidative damage.


Subject(s)
Albizzia/chemistry , Antiemetics/pharmacology , Brain/drug effects , Flowers/chemistry , Mitochondria/drug effects , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Plant Extracts/pharmacology , Vomiting/drug therapy , Animals , Biomarkers/metabolism , Catalepsy/metabolism , Chickens , Copper Sulfate/pharmacology , Dose-Response Relationship, Drug , Female , Flavonoids/analysis , Ipecac/pharmacology , Lipid Peroxidation/drug effects , Male , Phenols/analysis , Plant Extracts/chemistry , Vomiting/chemically induced
3.
Gen Physiol Biophys ; 37(3): 285-297, 2018 May.
Article in English | MEDLINE | ID: mdl-29938675

ABSTRACT

Given the fact that oxidative stress response induced by training/detraining has still not been clarified and may be influenced by gender, the aim of our investigation was to compare the effects of swimming training and detraining on oxidative and antioxidative parameters in rats, with a special focus on sex differences. Wistar albino rats (n = 64) were divided into 4 groups: control, trained group, groups exposed to 2 and 4 weeks of detraining. Each group included two subgroups: males and females. After sacrificing, hearts were isolated and retrogradely perfused according to Langendorff technique. Levels of superoxide anion radical, hydrogen peroxide, nitrites and thiobarbituric acid reactive substances were measured in plasma and coronary venous effluent, while reduced glutathione, activities of superoxide dismutase and catalase were measured in erythrocytes. Our results indicate that swimming training doesn't promote oxidative damage, nor act protectively within the heart. However, 2 and 4 weeks of detraining led to a partial lost in exercise-induced adaptation. It seems that moderate-intensity physical exercise of sufficient duration leads to beneficial adaptations, which may be partially lost during detraining period. Positive antioxidative effects of training remained longer in males. Findings of present study may help in elucidation of training and detraining effects on modulation of redox homeostasis, especially from aspect of gender differences.


Subject(s)
Physical Conditioning, Animal , Sex Characteristics , Animals , Antioxidants/metabolism , Biomarkers/metabolism , Catalepsy/metabolism , Female , Glutathione/metabolism , Hydrogen Peroxide/metabolism , Male , Myocardium/metabolism , Oxidation-Reduction , Oxidative Stress , Rats , Rats, Wistar , Superoxides/metabolism , Swimming , Thiobarbituric Acid Reactive Substances/metabolism
4.
Mol Biol (Mosk) ; 52(2): 246-256, 2018.
Article in Russian | MEDLINE | ID: mdl-29695693

ABSTRACT

The effects of chronic 5-HT1A receptor activation on the behavior, functional activity of 5-HT1A receptors, and expression of key genes of the brain 5-HT system were studied in mice of the catalepsy-prone CBA strain and the catalepsy-resistant C57BL/6 strain. Chronic treatment with 8-Hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) (1.0 mg/kg i.p., 14 days) led to a significant decrease in the hypothermic response to acute administration of 8-OH-DPAT in CBA and C57BL/6 mice, which indicates the desensiti-zation of 5-HT1A receptors in both strains. Pretreatment with the 5-HT7 receptor agonist SB 269970 did not affect the hypothermic response to the acute administration of 8-OH-DPAT, which suggests an independent functional response of 5-HT1A receptors. The treatment did not induce any changes in the behavior in the open field paradigm in CBA mice, but significantly increased the total path, the time spent in the center, and the number of rearings in C57BL/6 mice, which indicates the enhancement of locomotor and exploratory activity in C57BL/6 mice. The chronic activation of 5-HT1A receptor downregulated 5-HT1A gene expression, as well as the expression of the gene that encodes tryptophan hydroxylase 2, a key enzyme of 5-HT biosynthesis, in the midbrain and the expression of the gene that encodes the 5-HT2A receptor in the frontal cortex of CBA, but not C57BL/6 mice. The obtained data provide a new evidence on the receptor-gene cross talk in the brain 5-HT system that may underlie the loss of pharmacological efficacy of 5-HT1A receptor agonists. In turn, the loss of the behavioral response and compensatory alterations in key genes of the brain 5-HT system in CBA mice suggests that catalepsy-prone and -resistant genotypes demonstrate different sensibility to the effects of drugs.


Subject(s)
8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology , Catalepsy , Genetic Predisposition to Disease , Receptor, Serotonin, 5-HT1A , Serotonin 5-HT1 Receptor Agonists/pharmacology , Animals , Catalepsy/chemically induced , Catalepsy/genetics , Catalepsy/metabolism , Mice , Mice, Inbred CBA , Mice, Mutant Strains , Receptor, Serotonin, 5-HT1A/genetics , Receptor, Serotonin, 5-HT1A/metabolism
5.
Pharmacol Res ; 121: 1-13, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28414178

ABSTRACT

The effects of antipsychotic drugs (APDs) on the adolescent brain are poorly understood despite a dramatic increase in prescription of these drugs in adolescents over the past twenty years. Neuronal systems continue to be remodeled during adolescence. Therefore, when given in adolescence, antipsychotic drugs (APDs) have the potential to affect this remodeling. In this study we investigated the effects of chronic 22-day risperidone treatment (1.3mg/kg/day) in both adolescent and adult rats. We examined short- and long-term changes in behaviour (catalepsy, locomotion and conditioned avoidance response (CAR)), and dopaminergic and serotonergic neurochemistry in the striatum and the nucleus accumbens. Here, we report that, both during chronic treatment and after a lengthy drug-free interval, risperidone induced a sensitised cataleptic response regardless of the age of exposure. Selectively in adolescents, risperidone-induced catalepsy was inversely correlated with striatal dopamine turnover immediately after chronic treatment. After a drug-free interval, a significant proportion of rats with prior adolescent risperidone treatment also failed to acquire CAR to a defined criterion. Our data provide evidence that the same chronic risperidone treatment regimen can induce contrasting short- and long-term neural outcomes in the adolescent and adult brains.


Subject(s)
Antipsychotic Agents/adverse effects , Catalepsy/chemically induced , Risperidone/adverse effects , Age Factors , Animals , Antipsychotic Agents/administration & dosage , Biogenic Monoamines/analysis , Biogenic Monoamines/metabolism , Brain/drug effects , Brain/growth & development , Brain/metabolism , Brain/physiopathology , Catalepsy/blood , Catalepsy/metabolism , Catalepsy/physiopathology , Corticosterone/blood , Dopamine/metabolism , Locomotion/drug effects , Male , Rats , Rats, Sprague-Dawley , Risperidone/administration & dosage
6.
Toxicol Ind Health ; 33(2): 97-106, 2017 Feb.
Article in English | MEDLINE | ID: mdl-26419261

ABSTRACT

Hexavalent chromium (CrVI)-containing compounds, present in industrial settings and in the environment, are known as carcinogens and mutagens. The present study is designed to test the hypothesis that oxidative stress mediates CrVI-induced apoptosis in testis. Male Wistar rats received an intraperitoneal injection of potassium dichromate at doses of 1 and 2 mg kg-1. Superoxide anion production was assessed by the determination of the reduction of cytochrome c and iodonitrotetrazolium, lipid peroxidation (LPO), metallothioneins (MTs), and catalase (CAT) activity. Apoptosis was evaluated by DNA fragmentation detected by agarose gel electrophoresis. Germinal cells apoptosis was detected by toluidine blue staining. The expression of Bax and Bcl-2 proteins (Pts) was also investigated. After 15 days of treatment, an increase of LPO and MT levels occurred, while CAT activity was decreased. Testicular tissues of treated rats showed pronounced degradation of the DNA into oligonucleotides as seen in the typical electrophoretic DNA ladder pattern. Intense apoptosis was observed in germinal cells of Cr-exposed rats. Bax Pt expression was induced in spermatogonia and spermatocytes cells of CrVI-treated rats. In contrast, Bcl-2 Pt was occasionally observed in germ cells of CrVI-exposed rats. These results clearly suggest that CrVI subacute treatment causes oxidative stress in rat testis leading to apoptosis.


Subject(s)
Apoptosis/drug effects , Carcinogens, Environmental/toxicity , Chromium/toxicity , Testis/drug effects , Animals , Catalepsy/metabolism , DNA Fragmentation/drug effects , Electrophoresis, Agar Gel , Male , Rats , Rats, Wistar , Superoxides/analysis , Testis/chemistry
7.
Acta Pol Pharm ; 73(2): 529-35, 2016.
Article in English | MEDLINE | ID: mdl-27180446

ABSTRACT

The present study was undertaken to evaluate the possible protective effect of thymoquinone on chlorpromazine induced catalepsy, locomotor activity and cerebral oxidative stress in rats. The rats were divided into four groups, each group containing eight animals. The animals were evaluated after repeated administration of chlorpromazine (CPZ) 30 min before the administration of thymoquinone (TQ) for 21 days. Catalepsy was assessed using block method whereas the locomotor activity was assessed using acceleratory rotarod and actophotometer. Markers of oxidative stress parameters (LPO, GSH, GPx, GR, GST and CAT) were evaluated in the brain of rats. The cataleptic scores were significantly increased in CPZ treated rats when compared with normal control rats. Oral administration of TQ (5 and 10 mg/kg) significantly decreased cataleptic scores when compared with chlorpromazine (CPZ) treated rats. The muscle coordination and spontaneous locomotor activity was significantly decreased in CPZ treated rats when compared with normal control rats. Treatment with TQ significantly improved the muscle coordination and spontaneous locomotor activity when compared with CPZ treated rats. TQ treated rats significantly reduced the elevated levels of lipid peroxidation (LPO), increased levels of antioxidant enzymes i.e., reduced glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-S-transferase (GST) and catalase (CAT) when compared with CPZ treated rats. The results clearly suggest that supplementation with TQ can be used to preclude CPZ induced extrapyramidal side effects and may find a role in reducing the oxidative stress.


Subject(s)
Antioxidants/pharmacology , Behavior, Animal/drug effects , Benzoquinones/pharmacology , Brain/drug effects , Catalepsy/drug therapy , Chlorpromazine , Motor Activity/drug effects , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Animals , Biomarkers/metabolism , Brain/metabolism , Brain/physiopathology , Catalepsy/chemically induced , Catalepsy/metabolism , Catalepsy/physiopathology , Disease Models, Animal , Lipid Peroxidation/drug effects , Male , Rats, Wistar , Rotarod Performance Test
8.
Tsitologiia ; 58(7): 555-61, 2016.
Article in English, Russian | MEDLINE | ID: mdl-30198672

ABSTRACT

The content and the ratio of phytohormones, the activity of enzymes-antioxidants and lipid peroxidation, contents of proline and carotenoids in potato plants under the action of colchicines have been investigated. We have identified specific changes in hormonal balance of the plant initiated by the destructor of microtubules, colchicines (1 mM). We have found significant decreased in the amount of indoleacetic acid and zeatin, increase in the content of abscisic acid, no changes in the level of gibberellic acid, a decreased in the ratio between hormones-stimulants and abscisic acid. At this hormonal background, we observed activation of low molecular weight antioxidant system (increased levels of proline and carotenoids), while the peroxidase activity decreased slightly, and catalase activity did not change. Monitoring of reactions of lipid peroxidation showed the activation of its initial stages (accumulation of hydroperoxides), and then the process stabilized (the level of malondialdehyde did not change). We have concluded that the formation of hormonal status Solanum tuberosum, as well as the work of the antioxidant system, depend on the structural condition of the tubulin cytoskeleton.


Subject(s)
Antioxidants/metabolism , Colchicine/pharmacology , Microtubules/metabolism , Plant Growth Regulators/metabolism , Solanum tuberosum/metabolism , Carotenoids/metabolism , Catalepsy/metabolism , Peroxidases/metabolism , Plant Proteins/metabolism , Solanum tuberosum/cytology
9.
Pharm Res ; 31(10): 2605-17, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24792824

ABSTRACT

OBJECTIVES: Dopamine D2 receptor occupancy (D2RO) is the major determinant of efficacy and safety in schizophrenia drug therapy. Excessive D2RO (>80%) is known to cause catalepsy (CAT) in rats and extrapyramidal side effects (EPS) in human. The objective of this study was to use pharmacokinetic and pharmacodynamic modeling tools to relate CAT with D2RO in rats and to compare that with the relationship between D2RO and EPS in humans. METHODS: Severity of CAT was assessed in rats at hourly intervals over a period of 8 h after antipsychotic drug treatment. An indirect response model with and without Markov elements was used to explain the relationship of D2RO and CAT. RESULTS: Both models explained the CAT data well for olanzapine, paliperidone and risperidone. However, only the model with the Markov elements predicted the CAT severity well for clozapine and haloperidol. The relationship between CAT scores in rat and EPS scores in humans was implemented in a quantitative manner. Risk of EPS not exceeding 10% over placebo correlates with less than 86% D2RO and less than 30% probability of CAT events in rats. CONCLUSION: A quantitative relationship between rat CAT and human EPS was elucidated and may be used in drug discovery to predict the risk of EPS in humans from D2RO and CAT scores measured in rats.


Subject(s)
Antipsychotic Agents , Catalepsy/metabolism , Dopamine D2 Receptor Antagonists , Models, Biological , Receptors, Dopamine D2/metabolism , Animals , Antipsychotic Agents/adverse effects , Antipsychotic Agents/pharmacokinetics , Antipsychotic Agents/pharmacology , Benzodiazepines/adverse effects , Benzodiazepines/pharmacokinetics , Benzodiazepines/pharmacology , Brain/metabolism , Catalepsy/etiology , Computer Simulation , Dopamine D2 Receptor Antagonists/adverse effects , Dopamine D2 Receptor Antagonists/pharmacokinetics , Dopamine D2 Receptor Antagonists/pharmacology , Dose-Response Relationship, Drug , Humans , Isoxazoles/adverse effects , Isoxazoles/pharmacokinetics , Isoxazoles/pharmacology , Markov Chains , Olanzapine , Paliperidone Palmitate , Pyrimidines/adverse effects , Pyrimidines/pharmacokinetics , Pyrimidines/pharmacology , Rats , Risperidone/adverse effects , Risperidone/pharmacokinetics , Risperidone/pharmacology , Severity of Illness Index
10.
Behav Pharmacol ; 25(2): 182-5, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24603340

ABSTRACT

Several allosteric modulators (AMs) of the CB1 receptor have been characterized in vitro, including Org27569, which enhances CB1-specific binding of [H]CP55,940, but behaves as an insurmountable CB1-receptor antagonist in several biochemical assays. Although a growing body of research has investigated the molecular actions of this unusual AM, it is unknown whether these actions translate to the whole animal. The purpose of the present study was to determine whether Org27569 would produce effects in well-established mouse behavioral assays sensitive to CB1 orthosteric agonists and antagonists. Similar to the orthosteric CB1 antagonist/inverse agonist rimonabant, Org27569 reduced food intake; however, this anorectic effect occurred independently of the CB1 receptor. Org27569 did not elicit CB1-mediated effects alone and lacked efficacy in altering antinociceptive, cataleptic, and hypothermic actions of the orthosteric agonists anandamide, CP55,940, and Δ-tetrahydrocannabinol. Moreover, it did not alter the discriminative stimulus effects of anandamide in FAAH-deficient mice or Δ-tetrahydrocannabinol in wild-type mice in the drug discrimination paradigm. These findings question the utility of Org27569 as a 'gold standard' CB1 AM and underscore the need for the development of CB1 AMs with pharmacology that translates from the molecular level to the whole animal.


Subject(s)
Cannabinoid Receptor Modulators/pharmacology , Indoles/pharmacology , Piperidines/pharmacology , Receptor, Cannabinoid, CB1/metabolism , Allosteric Regulation , Amidohydrolases/genetics , Amidohydrolases/metabolism , Animals , Arachidonic Acids/pharmacology , Cannabinoid Receptor Agonists/pharmacology , Cannabinoid Receptor Antagonists/pharmacology , Cannabinoid Receptor Modulators/pharmacokinetics , Catalepsy/chemically induced , Catalepsy/drug therapy , Catalepsy/metabolism , Cyclohexanols/pharmacology , Dronabinol/pharmacology , Drug Evaluation , Eating/drug effects , Eating/physiology , Endocannabinoids/pharmacology , Female , Hypothermia/chemically induced , Hypothermia/drug therapy , Hypothermia/metabolism , Indoles/pharmacokinetics , Male , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Mice, Knockout , Nociception/drug effects , Nociception/physiology , Piperidines/pharmacokinetics , Polyunsaturated Alkamides/pharmacology , Pyrazoles/pharmacology , Receptor, Cannabinoid, CB1/agonists , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Receptor, Cannabinoid, CB1/genetics , Rimonabant
11.
Article in Russian | MEDLINE | ID: mdl-25975144

ABSTRACT

Catalepsy usually is caused by imbalance of dopamine (DA) and serotonin (5-HT) systems of brain. The aim of our work was to verify if this imbalance plays an important role in the mechanism of hereditary catalepsy in mice. Maintenance of DA, 5-HT and their main metabolites--5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylacetic acid, homovanilic acid was determined in cortex, hypothalamus, hippocampus, striatum, substantia nigra and nuclei raphes in catalepsy-resistant AKR/J mice strain and catalepsy-prone CBA/LacJ mice strain and recombinant mice AKR/J.CBA-D13Mit76 (D13) strain. The latest strain was selected by transferring of a fragment of the chromosome 13 from CBA/LacJ carrying the main gene of hereditary catalepsy to AKR/J genome. There were no interstrain differences in concentration of biogenic amines and their metabolites in all brain regions. As a result of our work the hypothesis about the important role of 5-HT and/or DA systems of brain in the mechanism of hereditary catalepsy in mice was denied.


Subject(s)
3,4-Dihydroxyphenylacetic Acid/metabolism , Catalepsy/metabolism , Dopamine/metabolism , Homovanillic Acid/metabolism , Hydroxyindoleacetic Acid/metabolism , Serotonin/metabolism , Animals , Catalepsy/genetics , Catalepsy/physiopathology , Cerebral Cortex/metabolism , Cerebral Cortex/physiopathology , Corpus Striatum/metabolism , Corpus Striatum/physiopathology , Crosses, Genetic , Genetic Predisposition to Disease , Hippocampus/metabolism , Hippocampus/physiopathology , Hypothalamus/metabolism , Hypothalamus/physiopathology , Male , Mice, Inbred AKR , Mice, Inbred CBA , Nucleus Accumbens/metabolism , Nucleus Accumbens/physiopathology , Nucleus Raphe Magnus/metabolism , Nucleus Raphe Magnus/physiopathology , Substantia Nigra/metabolism , Substantia Nigra/physiopathology
12.
Pharm Res ; 30(9): 2368-84, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23739987

ABSTRACT

PURPOSE: To elucidate the role of metabolism in the pharmacokinetics and pharmacodynamics of intranasal loxapine in conscious animals. METHODS: At pre-determined time points after intranasal or oral loxapine administration, levels of loxapine, loxapine metabolites, and neurotransmitters in rat brain were quantified after catalepsy assessments (block test and paw test). Cataleptogenicity of loxapine was also compared with its metabolites. RESULTS: Intranasally administered loxapine was efficiently absorbed into systemic circulation followed by entering brain, with tmax ≤15 min in all brain regions. Oral route delivered minimal amounts of loxapine to plasma and brain. Brain AUC0-240min values of 7-hydroxy-loxapine were similar after intranasal and oral administration. Intranasal loxapine tended to induce less catalepsy than oral loxapine, although statistical significance was not reached. The catalepsy score was positively and significantly correlated with the striatal concentration of 7-hydroxy-loxapine, but not with loxapine. 7-hydroxy-loxapine was more cataleptogenic than loxapine, while the presence of loxapine tended to reduce rather than intensify 7-hydroxy-loxapine-induced catalepsy. The increases in striatal dopamine turnover were comparable after intranasal and oral loxapine administration. CONCLUSIONS: The metabolite 7-hydroxy-loxapine, but not loxapine, was the main contributor to the catalepsy observed after intranasal and oral loxapine treatment. Intranasal route could effectively deliver loxapine to brain.


Subject(s)
Antipsychotic Agents/adverse effects , Antipsychotic Agents/pharmacokinetics , Brain/metabolism , Catalepsy/chemically induced , Loxapine/adverse effects , Loxapine/pharmacokinetics , Administration, Intranasal , Administration, Oral , Animals , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/metabolism , Brain/drug effects , Catalepsy/metabolism , Loxapine/administration & dosage , Loxapine/metabolism , Male , Rats , Rats, Wistar
13.
Biosci Biotechnol Biochem ; 77(2): 266-70, 2013.
Article in English | MEDLINE | ID: mdl-23391905

ABSTRACT

The populations of the Kii Peninsula in Japan and of Guam present high incidences of amyotrophic lateral sclerosis and Parkinsonism-dementia complex. It is thought that low levels of calcium (Ca) and magnesium (Mg) in the drinking water are involved in the pathogenesis of these diseases. The present study aimed to test the hypothesis that catalepsy, behavioral immobility and a Parkinsonian symptom results from functionally impaired dopaminergic neurons in mice fed low amounts of Ca and Mg (LCa/Mg). A group of mice fed a LCa/Mg diet for 6 weeks was compared to a control group on a standard diet. Cataleptic symptoms such as akinesia and rigidity were measured by the bar test. The anti-parkinsonian drugs dopamine (DA) precursor L-3,4-dihydroxy phenylamine (L-DOPA), the selective DA receptor D(2) agonist bromocriptine, and the DA releaser amantadine were tested for their effects on induced catalepsy. The mice developed catalepsy after 3 weeks on the LCa/Mg diet. LCa/Mg diet-induced catalepsy was improved by the administration of L-DOPA (50-200 mg/kg i.p.) in combination with benserazide (25 mg/kg i.p.), or of bromocriptine (0.25-4 mg/kg i.p.) or of amantadine (5-20 mg/kg i.p.). Immunohistochemical staining revealed that the intensity of tyrosine hydroxylase fluorescence was significantly decreased in the substantia nigra at the 6th week of LCa/Mg feeding in comparison with pair-fed controls. These results suggest that catalepsy in LCa/Mg mice results from hypofunction of the dopaminergic neurons. Moreover, our results support the hypothesis that LCa/Mg intake is one etiological factor in neurodegenerative disorders, including Parkinson's disease.


Subject(s)
Calcium/deficiency , Catalepsy/metabolism , Food, Formulated/adverse effects , Magnesium Deficiency/metabolism , Magnesium/metabolism , Parkinson Disease, Secondary/metabolism , Amantadine/pharmacology , Animals , Antiparkinson Agents/pharmacology , Benserazide/pharmacology , Bromocriptine/pharmacology , Catalepsy/chemically induced , Catalepsy/drug therapy , Dopamine Agonists/pharmacology , Levodopa/pharmacology , Magnesium Deficiency/chemically induced , Magnesium Deficiency/drug therapy , Male , Mice , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/drug therapy , Receptors, Dopamine/metabolism , Risk Factors , Substantia Nigra/drug effects , Substantia Nigra/enzymology , Tyrosine 3-Monooxygenase/antagonists & inhibitors , Tyrosine 3-Monooxygenase/metabolism
14.
Mol Biol (Mosk) ; 47(3): 467-74, 2013.
Article in Russian | MEDLINE | ID: mdl-23888778

ABSTRACT

Glycoprotein gp130 is involved in the intracellular transduction of signals from receptors ofinterleukin-6--related cytokines. The linkage between Il6st gene encoding gp130 and predisposition to excessive freezing (catalepsy) in mice was shown. The aim of present study was to investigate the Il6st mRNA concentration, the level and the rate of glycosilation of gp130 in five brain structures in catalepsy-resistant AKR/J mice strain and in catalepsy-prone CBA/LacJ, AKR.CBA-D13Mit76 with the CBA-derived Il6st gene variant in the AKR/J genome, and ASC created by selection of back-crosses between CBA and AKR strains on catalepsy. Highest concentrations of the nonglycosilated and the glycosilated gp130 protein levels were detected in the midbrain. High levels of Il6st mRNA were discovered in the midbrain, the striatum and the hypothalamus in all mouse strains. The level of Il6st mRNA in the striatum of AKR.CBA-D13Mit76 mice was significantly higher compared with AKR/J. An association between hereditary catalepsy and Il6st expression in the striatum in mice was suggested.


Subject(s)
Brain/metabolism , Catalepsy/metabolism , Cytokine Receptor gp130/biosynthesis , Freezing Reaction, Cataleptic , Gene Expression Regulation , Nerve Tissue Proteins/biosynthesis , RNA, Messenger/biosynthesis , Animals , Brain/pathology , Catalepsy/genetics , Catalepsy/pathology , Genetic Predisposition to Disease , Mice , Species Specificity
15.
J Pharmacol Exp Ther ; 342(1): 91-105, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22490380

ABSTRACT

All marketed antipsychotics act by blocking dopamine D(2) receptors. Fast dissociation from D(2) receptors may be one of the elements contributing to the lower incidence of extrapyramidal symptoms (EPS) exhibited by newer antipsychotics. Therefore, we screened for specific D(2) receptor blockers with a fast rate of dissociation. Radioligand binding experiments identified N-[1-(3,4-difluorobenzyl)piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine (JNJ-37822681) as a fast-dissociating D(2) ligand. Its D(2) receptor specificity was high compared with atypical antipsychotics, with little activity at receptors associated with unwanted effects [α(1), α(2), H(1), muscarinic, and 5-hydroxytryptamine (5-HT) type 2C] and for receptors that may interfere with the effects of D(2) antagonism (D(1), D(3), and 5-HT(2A)). JNJ-37822681 occupied D(2) receptors in rat brain at relatively low doses (ED(50) 0.39 mg/kg) and was effective in animal models of psychosis (e.g., inhibition of apomorphine-induced stereotypy or D-amphetamine/phencyclidine-induced hyperlocomotion). Prolactin levels increased from an ED(50) (0.17 mg/kg, peripheral D(2) receptors) close to the ED(50) required for apomorphine antagonism (0.19 mg/kg, central D(2) receptors), suggesting excellent brain disposition and minimal prolactin release at therapeutic doses. JNJ-37822681 induced catalepsy and inhibited avoidance behavior, but with a specificity margin relative to apomorphine antagonism that was larger than that obtained for haloperidol and similar to that obtained for olanzapine. This larger specificity margin (compared with haloperidol) may reflect lower EPS liability and less behavioral suppression after JNJ-37822681. JNJ-37822681 is a novel, potent, specific, centrally active, fast-dissociating D(2) antagonist with optimal brain disposition, and it is the first compound that allows the evaluation of the potential value of fast D(2) antagonism for the treatment of schizophrenia and bipolar disorder.


Subject(s)
Dopamine Antagonists/pharmacology , Dopamine D2 Receptor Antagonists , Piperidines/pharmacology , Pyridazines/pharmacology , Schizophrenia/drug therapy , Animals , Antipsychotic Agents/pharmacology , Apomorphine/antagonists & inhibitors , Apomorphine/metabolism , Behavior, Animal/drug effects , Benzodiazepines/adverse effects , Brain/drug effects , Brain/metabolism , CHO Cells , Catalepsy/chemically induced , Catalepsy/drug therapy , Catalepsy/metabolism , Cells, Cultured , Cricetinae , Female , Haloperidol/adverse effects , Haloperidol/metabolism , Humans , Ligands , Locomotion/drug effects , Male , Olanzapine , Prolactin/pharmacology , Rats , Rats, Inbred Lew , Rats, Sprague-Dawley , Rats, Wistar , Receptors, Dopamine D2/metabolism , Schizophrenia/metabolism , Serotonin/metabolism
16.
Biochemistry (Mosc) ; 77(5): 419-24, 2012 May.
Article in English | MEDLINE | ID: mdl-22813582

ABSTRACT

The brain is protected by a physiological blood-brain barrier (BBB) against toxins and some metabolites circulating in the blood. At the same time, the BBB limits penetration into the brain of many neuroactive drugs. Efficient ways to increase BBB permeability for delivery of drugs of different chemical nature into the brain are unknown. This work deals with delivery into the brain of 10(-2) M dopamine, a substance that does not penetrate the BBB under normal circumstances. It was studied in two independent experiments: (i) penetration of (3)H-labeled dopamine from its mixture with 10(-5) M H2O2 into hypothalamus and striatum structures of intact rat brain, and (ii) effect of unlabeled dopamine from a mixture with H(2)O(2) on the rat motor activity in a haloperidol catalepsy model. It was shown that (i) at the third minute after nasal application of the dopamine + H(2)O(2) mixture, the dopamine level increases 45-fold in the hypothalamus and almost 30-fold in the striatum and (ii) motility of animals in the catalepsy haloperidol model is recovered 90 sec after intranasal introduction of dopamine. No such effects were observed after replacement of H(2)O(2) by 0.9% NaCl solution. Thus, it was shown on the example of dopamine that its introduction into the nasal cavity simultaneously with H(2)O(2) provides for rapid delivery of the drug into the brain. These results expand our knowledge concerning the biological role of exoROS in modulating BBB permeability and may contribute to the development of a new therapeutic strategy for neurological diseases.


Subject(s)
Blood-Brain Barrier/metabolism , 3,4-Dihydroxyphenylacetic Acid/analysis , Administration, Intranasal , Animals , Catalepsy/chemically induced , Catalepsy/metabolism , Catalepsy/pathology , Chromatography, High Pressure Liquid , Corpus Striatum/metabolism , Disease Models, Animal , Dopamine/analysis , Dopamine/pharmacology , Dopamine Agents/analysis , Dopamine Agents/pharmacology , Haloperidol/toxicity , Hydrogen Peroxide/pharmacology , Hypothalamus/metabolism , Isotope Labeling , Male , Motor Activity/drug effects , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Tritium/chemistry
17.
Article in Russian | MEDLINE | ID: mdl-22690554

ABSTRACT

Selective activation of serotonin 5-HT(1A)-receptors produced different effects on immunological reactivity in mice of ASC strain with genetic predisposition to depressive-like behavior, and parental CBA and AKR strains displaying no depressive reactions. Administration of 5-HT(1A)-receptors agonist 8-OH-DPAT at low dose (0.1 mg/kg) affecting upon presynaptic receptors resulted in immunostimulation in CBA mice and did not change the immune response level in mice of ASC strain. Activation of postsynaptic 5-HT(1A)-receptors with higher dose of 8-OH-DPAT (1.0 mg/kg) caused immunosuppression in CBA and AKR strains while under the same conditions the immune response of ASC mice was increased. Decrease the immune reactions in ASC mice was observed only after application of 8-OHDPAT at dose of 5 mg/kg. The changes of functional activity of pre- and postsynaptic 5-HT(1A)-receptors under a high predisposition to depressive-like behavior providing different effects of this receptor activation on immune function are discussed.


Subject(s)
Depression/immunology , Depression/metabolism , Receptor, Serotonin, 5-HT1A/immunology , 8-Hydroxy-2-(di-n-propylamino)tetralin/administration & dosage , Animals , Catalepsy/genetics , Catalepsy/metabolism , Depression/etiology , Dose-Response Relationship, Drug , Genetic Predisposition to Disease , Immunomodulation/drug effects , Male , Mice , Mice, Inbred AKR , Mice, Inbred CBA , Receptor, Serotonin, 5-HT1A/metabolism , Serotonin 5-HT1 Receptor Agonists/pharmacology , Species Specificity , Stress, Psychological/complications
18.
Patol Fiziol Eksp Ter ; (3): 75-80, 2012.
Article in Russian | MEDLINE | ID: mdl-23072116

ABSTRACT

The influence of haloperidol intracutaneous injections on the development of spontaneous catalepsy phenomenon in SHR mice which received intraperitoneal injections of d,l-amphetamine (10 mg/kg) and haloperidol (5 mg/kg) alternately during 12 days, was studied ("neurochemical aggression"). It was demonstrated that alternating injections of d,l-amphetamine and haloperidol decrease the spontaneous catalepsy duration. Daily intracutaneous injections of haloperidol (0,25 mg/kg) prevented these changes but disrupted the spontaneous catalepsy phenomenon recovery by the 10-th day of measurements. A lower dosage (0,1 mg/kg) of haloperidol did not affect the results of the research. A conclusion was made that subchronic injections of haloperidol might have a protective effect in acute period of "neurochemical aggression" but slow down brain functioning recovery.


Subject(s)
Amphetamine/pharmacology , Catalepsy/metabolism , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Haloperidol/pharmacology , Amphetamine/administration & dosage , Animals , Behavior, Animal/drug effects , Catalepsy/prevention & control , Dopamine/metabolism , Dopamine Agonists/administration & dosage , Dopamine Antagonists/administration & dosage , Dose-Response Relationship, Drug , Haloperidol/administration & dosage , Injections, Intraperitoneal , Mice , Mice, Inbred Strains , Time Factors
19.
J Neurosci ; 30(8): 3146-55, 2010 Feb 24.
Article in English | MEDLINE | ID: mdl-20181611

ABSTRACT

Fatty acid binding proteins (FABPs) are essential for energy production and long-chain polyunsaturated fatty acid-related signaling in the brain and other tissues. Of various FABPs, heart-type fatty acid binding protein (H-FABP, FABP3) is highly expressed in neurons of mature brain and plays a role in arachidonic acid incorporation into brain and heart cells. However, the precise function of H-FABP in brain remains unclear. We previously demonstrated that H-FABP is associated with the dopamine D(2) receptor long isoform (D2LR) in vitro. Here, we confirm that H-FABP binds to dopamine D(2) receptor (D2R) in brain extracts and colocalizes immunohistochemically with D2R in the dorsal striatum. We show that H-FABP is highly expressed in acetylcholinergic interneurons and terminals of glutamatergic neurons in the dorsal striatum of mouse brain but absent in dopamine neuron terminals and spines in the same region. H-FABP knock-out (KO) mice showed lower responsiveness to methamphetamine-induced sensitization and enhanced haloperidol-induced catalepsy compared with wild-type mice, indicative of D2R dysfunction. Consistent with the latter, aberrant increased acetylcholine (ACh) release and depolarization-induced glutamate (Glu) release were observed in the dorsal striatum of H-FABP KO mice. Furthermore, phosphorylation of CaMKII (Ca(2+)/calmodulin-dependent protein kinase II) and ERK (extracellular signal-regulated kinase) was significantly increased in the dorsal striatum. We confirmed elevated ERK phosphorylation following quinpirole-mediated D2R stimulation in H-FABP-overexpressing SHSY-5Y human neuroblastoma cells. Together, H-FABP is highly expressed in ACh interneurons and glutamatergic terminals, thereby regulating dopamine D2R function in the striatum.


Subject(s)
Brain Chemistry/physiology , Dopamine/metabolism , Fatty Acid-Binding Proteins/metabolism , Neostriatum/metabolism , Receptors, Dopamine D2/metabolism , Synaptic Transmission/physiology , Acetylcholine/metabolism , Acetylcholine/pharmacology , Animals , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Catalepsy/chemically induced , Catalepsy/metabolism , Catalepsy/physiopathology , Cell Line, Tumor , Extracellular Signal-Regulated MAP Kinases/metabolism , Fatty Acid Binding Protein 3 , Fatty Acid-Binding Proteins/genetics , Glutamic Acid/metabolism , Haloperidol/pharmacology , Humans , Immunohistochemistry , Interneurons/cytology , Interneurons/metabolism , Ligands , Methamphetamine/pharmacology , Mice , Mice, Knockout , Phosphorylation , Protein Binding/physiology , Receptors, Dopamine D2/genetics
20.
Naunyn Schmiedebergs Arch Pharmacol ; 394(4): 717-734, 2021 04.
Article in English | MEDLINE | ID: mdl-33146779

ABSTRACT

Over the years, mounting evidences have suggested a strong association between chronic chlorpromazine therapy, a popular first-generation antipsychotic drug, and psycho-neuroendocrine changes. In this study, we aim to examine whether treatment with taurine and coenzyme Q10 (COQ-10), compounds with steroidogenic-gonadotropin hormone-enhancing properties, can attenuate the negative impacts of chlorpromazine on steroidogenic, gonadotropin, thyroid and HPA-axis hormones, dopamine levels, catalepsy behavior and neuronal cells of the hypothalamus and pituitary gland in the preventive and reversal treatments in male Wister rats. In the drug treatment alone or preventive protocol, rats received oral administration of saline (10 mL/kg), taurine (150 mg/kg/day), COQ-10 (10 mg/kg/day), or both (taurine + COQ-10/day) alone for 56 consecutive days, or in combination with oral chlorpromazine (30 mg/kg/day) treatment from days 29 to 56. In the reversal protocol, the animals received chlorpromazine or saline for 56 days prior to taurine, COQ-10, or the combination from days 29 to 56. Thereafter, serum prolactin, steroidogenic (testosterone, estrogen, progesterone), gonadotropin (luteinizing hormone, LH, follicle-stimulating hormone, FSH), thyroid (thyrotropin-stimulating hormone, tetraiodothyronine, triiodothyronine) hormones, corticosterone, brain dopamine levels and cataleptic behavior were investigated. The histopathological features of the hypothalamus and pituitary gland were also evaluated. Taurine, COQ-10, or their combination prevented and reversed chlorpromazine-induced hyperprolactinemia, decrease in FSH, LH, testosterone, progesterone and dopamine concentrations, as well as the increase in estrogen levels. Taurine and COQ-10 reduced the changes in thyroid hormones, corticosterone release, histological distortions of the hypothalamus and the pituitary gland of chlorpromazine-treated rats. Taurine and COQ-10 attenuated chlorpromazine-induced catalepsy. The study showed that taurine and COQ-10 prevented and reversed chlorpromazine-induced changes in reproductive, thyroid hormones, dopamine level, corticosterone release, neurodegenerations, and cataleptic behavior in rats.


Subject(s)
Antipsychotic Agents/adverse effects , Catalepsy/drug therapy , Chlorpromazine/adverse effects , Neuroprotective Agents/therapeutic use , Taurine/therapeutic use , Ubiquinone/analogs & derivatives , Animals , Behavior, Animal/drug effects , Brain/drug effects , Brain/metabolism , Brain/pathology , Catalepsy/chemically induced , Catalepsy/metabolism , Catalepsy/pathology , Dopamine/metabolism , Drug Synergism , Drug Therapy, Combination , Hormones/blood , Male , Neuroprotective Agents/pharmacology , Rats, Wistar , Taurine/pharmacology , Ubiquinone/pharmacology , Ubiquinone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL